Money Concepts Capital’s ADMA Biologics ADMA Stock Holding History

Money Concepts Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,875	Closed	-$15K	–	490
2022 Q4	$15K	Buy	+3,875	New	+$12K	﹤0.01%	1818

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Money Concepts Capital's ADMA Position: Q1 2023 in Review

Money Concepts Capital sold out of ADMA Biologics (ADMA) in Q1 2023, closing a stake of 3,875 shares — an estimated $15K sold.

Money Concepts Capital first reported a position in ADMA in Q4 2022 and held it in 1 quarter. The position peaked at $15K in Q4 2022. 163 funds tracked by Wall St. Rank hold ADMA as of Q1 2023.

Money Concepts Capital reported no remaining ADMA Biologics position as of Q1 2023 after selling out during the quarter.
Money Concepts Capital sold 3,875 ADMA Biologics shares in Q1 2023, an estimated $15K.
Money Concepts Capital first reported a position in ADMA Biologics in Q4 2022 and held it in 1 quarter.
Money Concepts Capital's ADMA Biologics position peaked at $15K in Q4 2022.
163 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.